UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice

Diabetes (New York, N.Y.), 2008-08, Vol.57 (8), p.2211-2219

2008

Volltextzugriff (PDF)

Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists

Bioorganic & medicinal chemistry letters, 2010-02, Vol.20 (3), p.1298-1301

2010

Volltextzugriff (PDF)

(2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Journal of medicinal chemistry, 2005-01, Vol.48 (1), p.141-151

2005

Volltextzugriff (PDF)

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes : Potential importance of selectivity over dipeptidyl peptidases 8 and 9

Diabetes (New York, N.Y.), 2005-10, Vol.54 (10), p.2988-2994

2005

Volltextzugriff (PDF)

Differential effects of oxyntomodulin and GLP-1 on glucose metabolism

American journal of physiology: endocrinology and metabolism, 2012-07, Vol.303 (2), p.E265-E271

2012

Volltextzugriff (PDF)

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes

European journal of pharmacology, 2009-11, Vol.623 (1), p.148-154

2009

Volltextzugriff (PDF)

Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus

Bioorganic & medicinal chemistry letters, 2017-05, Vol.27 (9), p.2069-2073

2017

Volltextzugriff (PDF)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice

Endocrinology, diabetes & metabolism, 2018-01, Vol.1 (1), p.e00002-n/a

2018

Volltextzugriff (PDF)

Quantifying rates of glucose production in vivo following an intraperitoneal tracer bolus

American journal of physiology: endocrinology and metabolism, 2016-12, Vol.311 (6), p.E911-E921

2016

Volltextzugriff (PDF)

Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors

Bioorganic & medicinal chemistry letters, 2006-10, Vol.16 (20), p.5373-5377

2006

Volltextzugriff (PDF)

Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus

Bioorganic & medicinal chemistry letters, 2017-05, Vol.27 (9), p.2063-2068

2017

Volltextzugriff (PDF)

SAR exploration at the C-3 position of tetrahydro-β-carboline sstr3 antagonists

Bioorganic & medicinal chemistry letters, 2016-03, Vol.26 (6), p.1529-1535

2016

Volltextzugriff (PDF)

Discovery of Potent and Selective Dipeptidyl Peptidase IV Inhibitors Derived from β-Aminoamides Bearing Subsituted Triazolopiperazines

Journal of medicinal chemistry, 2008-02, Vol.51 (3), p.589-602

2008

Volltextzugriff (PDF)

Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes

ACS medicinal chemistry letters, 2016-12, Vol.7 (12), p.1107-1111

2016

Volltextzugriff (PDF)

3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists

Bioorganic & medicinal chemistry letters, 2011-06, Vol.21 (11), p.3390-3394

2011

Volltextzugriff (PDF)

Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIA™ (sitagliptin phosphate)

Bioorganic & medicinal chemistry letters, 2007-06, Vol.17 (12), p.3373-3377

2007

Volltextzugriff (PDF)

Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors

Bioorganic & medicinal chemistry letters, 2009-08, Vol.19 (15), p.4097-4101

2009

Volltextzugriff (PDF)

Design, synthesis, and biological evaluation of triazolopiperazine-based β-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors

Bioorganic & medicinal chemistry letters, 2007-11, Vol.17 (21), p.5934-5939

2007

Volltextzugriff (PDF)

Investigation of Cardiovascular Effects of Tetrahydro-β-carboline sstr3 antagonists

ACS medicinal chemistry letters, 2014-07, Vol.5 (7), p.748-753

2014

Volltextzugriff (PDF)

Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors

Bioorganic & medicinal chemistry letters, 2004-03, Vol.14 (5), p.1265-1268

2004

Volltextzugriff (PDF)

Discovery of potent and selective orally bioavailable β-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors

Bioorganic & medicinal chemistry letters, 2005-06, Vol.15 (12), p.3048-3052

2005

Volltextzugriff (PDF)

Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists

ACS medicinal chemistry letters, 2014-06, Vol.5 (6), p.690-695

2014

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(47)

Sprache

Englisch
(47)

Erscheinungsjahr

n.n

Thema

Science & Technology
(37)
Life Sciences & Biomedicine
(36)
Animals
(32)
Mice
(27)
Pharmacology & Pharmacy
(26)
Chemistry, Medicinal
(23)
Biological And Medical Sciences
(21)
Medical Sciences
(19)
Humans
(18)
Mice, Inbred C57bl
(16)
Pharmacology. Drug Treatments
(16)
Chemistry
(15)
Chemistry, Organic
(15)
General And Cellular Metabolism. Vitamins
(15)
Physical Sciences
(15)
Rats
(14)
Male
(12)
Structure-Activity Relationship
(11)
Type 2 Diabetes
(10)
Dogs
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice

Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists

(2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes : Potential importance of selectivity over dipeptidyl peptidases 8 and 9

Differential effects of oxyntomodulin and GLP-1 on glucose metabolism

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes

Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice

Quantifying rates of glucose production in vivo following an intraperitoneal tracer bolus

Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors

Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus

(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]- pyridin-6-ylphenyl)butanamide: A Selective α-Amino Amide Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

SAR exploration at the C-3 position of tetrahydro-β-carboline sstr3 antagonists

Discovery of Potent and Selective Dipeptidyl Peptidase IV Inhibitors Derived from β-Aminoamides Bearing Subsituted Triazolopiperazines

Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes

3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists

Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIA™ (sitagliptin phosphate)

Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes

Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors

Design, synthesis, and biological evaluation of triazolopiperazine-based β-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors

Investigation of Cardiovascular Effects of Tetrahydro-β-carboline sstr3 antagonists

Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors

Discovery of potent and selective orally bioavailable β-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors

The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes

Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists

Suchergebnisse filtern